There was a trend for hallucinations, ICD, and psychiatric disturbances to occur more frequently in GBA1-PD compared to the mutation-negative control group and idiopathic late-onset PD, but this was not statistically significant; advanced therapeutic interventions, including deep brain stimulation (DBS) and levodopa–carbidopa intestinal gel (LCIG) therapy, were more frequently required by this group [45]. The gene discussed is GBA1; the disease is Parkinson disease.